

Plasma 8-isoPGF₂α and serum melatonin levels in patients with minimal cognitive impairment and Alzheimer disease

Fevziye Burcu ŞİRİN^{1*}, Duygu KUMBUL DOĞUÇ², Hüseyin VURAL², İbrahim EREN³, İkbâl İNANLI³, Recep SÜTÇÜ¹, Namık DELİBAŞ⁴

¹Department of Biochemistry, Faculty of Medicine, Atatürk Training and Research Hospital, Katip Çelebi University, İzmir, Turkey

²Department of Biochemistry, Faculty of Medicine, Süleyman Demirel University, Isparta, Turkey

³Department of Psychiatry, Konya Training and Research Hospital, Konya, Turkey

⁴Department of Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Received: 15.07.2014

Accepted: 08.12.2014

Published Online: 00.00.2015

Printed: 00.00.2015

Background/aim: F₂α-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by antioxidative and antiamyloidogenic influences. By measuring these in patients diagnosed with minimal cognitive impairment (MCI) and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of Alzheimer disease (AD) in the MCI stage or not.

Materials and methods: Three groups (n = 63) were created: the AD group, MCI group, and control group. Serum melatonin levels were measured by radioimmunoassay method, and plasma total 8-isoPGF₂α levels were measured by enzyme immunoassay method.

Results: Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in 8-isoPGF₂α levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination (MMSE) scores and 8-isoPGF₂α levels (r = -0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r = 0.317, P = 0.011) were found.

Conclusion: Although the plasma 8-isoPGF₂α and serum melatonin levels in MCI were not found to be good early diagnostic markers to indicate risk of AD, results were found to support the role of oxidative stress in AD.

Key words: Alzheimer disease, minimal cognitive impairment, oxidative stress, isoprostane, melatonin

1. Introduction

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment. Before AD diagnosis, there is a long period with neuropathological changes (1–3).

Minimal cognitive impairment (MCI) is the clinical status of nondemented individuals who have memory deficits confirmed by objective tests. These memory deficits should not impair entire cognitive function or daily living activities (2). Annual conversion rate of MCI to dementia is reported as 10%–15% in different studies (4). The degenerative neuropathology of AD in the brain starts 20–30 years earlier than the clinical onset (5). Thus, MCI state is an important stage to determine and treat in people who are at risk of developing dementia.

Oxidative damage is present in early AD and also in MCI, and the role of oxidative stress is suggested in the etiopathogenesis of AD. When the balance between oxidant and antioxidant status shifts to the oxidant side,

oxidative stress manifests itself in the form of protein oxidation, DNA oxidation, and lipid peroxidation (6). Due to high polyunsaturated fatty acid content of brain, which is sensitive to oxidative stress, primarily lipid peroxidation occurs in the brain (7–9).

Isoprostanes, prostaglandin isomers, are considered to be the most accurate indicators of oxidative stress (10). In vitro and in vivo measurements of isoprostane are sensitive and specific for lipid peroxidation (11). Isoprostane F₂α-III and 8-isoprostaglandin F₂α are major products formed by free radical-catalyzed peroxidation of esterified arachidonic acid in membrane phospholipids (12).

The other parameter focused on is melatonin, which is suggested as an important direct free radical scavenger and indirect antioxidant (13–16). Melatonin is shown to be significantly effective at reducing oxidative damage in experimental models of the brain (15). In addition to reduced melatonin secretion during aging, more prominent decreases are reported in dementia (13,17). Daytime

* Correspondence: burcufenercioglu@yahoo.com

and nighttime melatonin levels are found to be lower in those aged 60 and above than in younger individuals, and patients with AD are also shown to have lower melatonin levels than individuals without the disease (13,18).

In this study we analyzed the plasma 8-isoPGF_{2α} levels and serum melatonin levels in nondemented control individuals and in patients diagnosed with MCI and Alzheimer-type dementia in order to demonstrate whether the measurement of these markers contributes to early diagnosis in the MCI stage or not.

2. Materials and methods

The study was conducted with the cooperation of the Biochemistry and Psychiatry Departments of the Süleyman Demirel University Medicine Faculty (Isparta, Turkey). The study protocol was approved by the Süleyman Demirel University Board of Ethics.

2.1. Subjects

Subjects older than 60 years of age (n = 63) from among residents of Isparta Atabey Rest Home, admissions to the Psychiatry Department, and field research were recruited to the study consecutively after a systematic physical and psychiatric examination by a psychiatry doctor.

For the assessment of cognitive status, a geriatric depression scale (19), global deterioration scale (20), activities of daily life scale (21), clock drawing test (22), behavioral pathology in AD scale (BEHAVE-AD) (23), and mini-mental state examination (MMSE) (24,25) were used. Patients whose life expectancy appeared to be less than 3 months because of life-threatening diseases, those taking steroids or vitamins, those whose cognitive functions could not be assessed because of blindness or deafness, and those with neurological or psychiatric disorders other than dementia were excluded.

In the study, three groups were created: the AD group (n = 20), MCI group (n = 21), and control group (n = 22). The diagnosis of MCI was established according to the Peterson criteria (26) and the diagnosis of dementia of the Alzheimer type was established according to DSM-IV criteria (22). The patients whose MMSE score was 24 or lower were accepted as having impaired cognitive function. The patients whose MMSE scores were higher than 26, who had normal cognitive functions, and who did not meet DSM-IV and Peterson diagnostic criteria were included in the control group. The AD group consisted of 20 patients (8 women and 12 men) with mean age of 79.05 ± 8.93 years and MMSE scores of 14.7 ± 4.3 . The MCI group consisted of 21 patients (12 women and 9 men) with mean age of 73.95 ± 7.19 years and MMSE scores of 22.0 ± 1.3 . The control group consisted of 22 individuals (9 women and 13 men) with mean age of 71.59 ± 6.65 years and MMSE scores of 27.9 ± 1.3 .

2.2. Sample collection and preparation

After overnight fasting, between 0800 and 0900 hours venous blood samples were drawn into EDTA-containing tubes and polystyrene tubes. After centrifugation at $3000 \times g$ for 10 min, plasma and serum samples were separated. Butylated hydroxytoluene (Sigma, Germany) was added to plasma samples, which were stored for isoprostane study (0.5% of plasma volume). Serum and plasma samples were stored and frozen at -80°C until assayed.

2.3. Measurement of plasma total 8-isoPGF_{2α} levels

Plasma total 8-isoPGF_{2α} levels were measured using the Direct 8-iso-Prostaglandin F_{2α} Enzyme Immunoassay Kit, catalog number 900-091 (Correlate, Assay Designs, USA).

2.4. Measurement of serum melatonin levels

Serum melatonin concentrations were measured using the Melatonin Direct Radioimmunoassay (Serum/Plasma) Kit, REF RE29301 (IBL, Germany).

2.5. Statistical analysis

Statistical analysis was performed with SPSS 11.0 for Windows. For three-group comparison, ANOVA and ANCOVA tests were used, and for pairwise comparisons the post hoc Bonferroni test was used. Chi-square test was used for comparison of sex characteristics and Kruskal–Wallis ANOVA was used for comparison of age characteristics in the groups. Correlations between variables were assessed with Pearson's correlation coefficients (r) and Mann–Whitney U tests. Data are expressed as mean \pm standard deviation (SD). $P < 0.05$ was accepted as significant.

3. Results

Melatonin levels were significantly higher in the MCI group than in the AD group ($P = 0.009$). The 8-isoPGF_{2α} levels were significantly higher in the AD group than in the control group ($P = 0.022$). A negative correlation between MMSE scores and 8-isoPGF_{2α} levels ($r = -0.459$, $p < 0.001$) and a positive correlation between MMSE scores and melatonin levels was found ($r = 0.317$, $P = 0.011$). Data were analyzed using ANCOVA and effect of age on melatonin was not significant ($F = 1.59$, $P = 0.960$). The results are shown in the Table.

4. Discussion

In several studies, cerebrospinal fluid (CSF) isoprostanes in patients with postmortem definitive diagnosis of AD and also plasma and urinary isoprostanes in living probable AD patients were measured. Elevated isoprostanes in the brain and CSF obtained during autopsy of patients diagnosed with AD have been reported (27,28). However, postmortem studies could not define whether the high isoprostane levels in CSF represent an early step in the neurodegeneration process as a result of oxidative stress by

Table. Age and 8-isoPGF_{2α} and melatonin levels in study groups.

	Control group	MCI group	AD group
Age	71.59 ± 6.65	73.95 ± 7.19	79.05 ± 8.93 ^a
8-isoPGF _{2α} (pg/mL)	2014.9 ± 809.1	2580.7 ± 1239.7	3254.8 ± 2066.1 ^b
Melatonin (pg/mL)	11.88 ± 2.35	12.73 ± 5.57	9.02 ± 2.91 ^c

Data are given as mean ± SD.

a: Significant difference when compared to control group (P = 0.006).

b: Significant difference when compared to control group (P = 0.022).

c: Significant difference when compared to MCI group (P = 0.009).

*: Effect of age on melatonin was not significant (ANCOVA, F = 1.59, P = 0.96).

lipid peroxidation or the final event. An increase in plasma or urine F₂-isoprostanes in patients with AD or MCI has also been reported (29–31). However, in the literature there are conflicting findings in CSF, peripheral plasma, and urine F₂-isoprostane levels in living individuals with clinically diagnosed AD (32,33). In addition, it was suggested in a recent study that the CSF levels of F₂-isoprostanes and beta-amyloid 1-42 are associated with the severity of neuropsychological symptoms, and also that the median levels of F₂-isoprostane and F₄-neuroprostanes were significantly higher in the cognitive impairment group than the control group (34).

In our study, a statistically negative correlation between MMSE scores and plasma

8-isoPGF_{2α} levels suggests that an increase in oxidative stress might be associated with cognitive decline. Plasma 8-isoPGF_{2α} levels of both the AD and MCI groups were higher than in the control group, but statistical significance was found only between the AD group and control group. The MCI group diagnosed clinically needs to be determined precisely. Patient selection criteria, assay method type, and the effect of additional diseases in elderly patients can alter the results of studies.

In addition to its major role in the regulation of circadian rhythms, the antioxidative and neuroprotective roles of melatonin in preventing the accumulation of amyloid have been demonstrated. In AD patients and elderly people, low melatonin values and impaired melatonin rhythm have also been shown. Before appearance of clinical symptoms, the changes in melatonin may be an early event in the development of AD (13,15,35). However, no association was found between postmortem CSF melatonin levels and the onset, duration, and severity of disease (17). Ventricular CSF melatonin levels were determined in patients with postmortem neuropathological staging and it was suggested that the decrease in CSF melatonin levels might be an early event in the development of AD (36). Wu et al. investigated the correlation between CSF and pineal melatonin content and plasma-CSF melatonin levels and suggested melatonin as an early marker in AD due to decreased melatonin levels since the earliest stage

of AD (37). On the other hand, recent clinical studies suggested melatonin use for the preventive treatment of major neurodegenerative disorders (38). Wade et al. investigated the addition of prolonged-release melatonin to conventional anti-AD therapy (acetylcholinesterase inhibitor with or without memantine) and determined cognitive function improvement in mild to moderate AD cases (39).

In our study, both the control group and MCI group mean serum melatonin levels were higher than in the AD group. However, a significant difference was only found between the MCI and AD groups; the differences between the AD and control and the MCI and control groups were not significant. Existence of a positive correlation between MMSE score and levels of melatonin shows a protective effect in terms of cognitive status. Absence of a significant difference between the AD and control group, slightly higher mean melatonin levels in the MCI group compared to the control group, and the coincidence of values in the data from the three groups suggest that serum melatonin levels are not predictive in the MCI stage.

In our study, the levels of melatonin were measured only in the morning. In several studies, nocturnal melatonin levels in AD have shown selective decrease (40,41). However, during the day, increased melatonin levels were also shown. In melatonin production, in addition to the changes with age, time changes in the rhythm of melatonin are reported (37,42). Pineal gland size and melatonin secretion of individuals has also been determined genetically (13). Perhaps especially in MCI individuals, longitudinal studies showing changes in melatonin rhythm may be more meaningful.

As with many peripheral markers investigated for early diagnosis of AD, our findings are limited due to other tissue interactions and lack of specificity to the brain.

In conclusion, although the plasma 8-isoPGF_{2α} and serum melatonin levels in MCI were not found to be good early diagnostic markers to show risk of AD, in combination with other diagnostic markers these parameters may be supportive. This study also supports the suggestions about the role of oxidative stress in AD.

References

1. Selekler K. Alzheimer hastalığının öncesi: hafif kognitif bozukluk. *Hacettepe Tıp Dergisi* 2004; 35: 199–206 (in Turkish).
2. Petersen RC. Mild cognitive impairment: where are we? *Alzheimer Dis Assoc Disord* 2005; 19: 166–169.
3. Chertkow H. Mild cognitive impairment. *Curr Opin Neurol* 2002; 15: 401–407.
4. Cardinalli DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. *Am J Neurodegener Dis* 2012; 1: 280–291.
5. Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. *Neurobiol Aging* 1997; 18: 85–88.
6. Montine TJ, Neely MD, Quinn JF, Beal F, Markesbery WR. Lipid peroxidation in aging brain and Alzheimer's Disease. *Free Radic Biol Med* 2002; 33: 620–626.
7. Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. *Am J Med* 2000; 109: 577–585.
8. Smith MA, Rottkamp C, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. *Biochim Biophys Acta* 2000; 1502: 139–144.
9. Christen Y. Oxidative stress and Alzheimer disease. *Am J Clin Nutr* 2000; 71: 621–629.
10. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in aging, neurodegenerative and vascular diseases: an overview. *J Chromatogr B Analyt Technol Biomed Life Sci* 2005; 827: 65–75.
11. Praticò D, Lawson JA, Rokach J, FitzGerald GA. The isoprostanes in biology and medicine. *Trends Endocrinol Metab* 2001; 12: 243–247.
12. Pratico D, Lawson JA, FitzGerald GA. Cyclooxygenase-dependent formation of the isoprostane, 8-epi PGF_{2α}. *J Biol Chem* 1995; 270: 9800–9808.
13. Reiter RJ. Melatonin: clinical relevance. *Best Pract Res Clin Endocrinol Metab* 2003; 17: 273–285.
14. Matuszak Z, Reszka KJ, Chignell CF. Reaction of melatonin and related indoles with hydroxyl radicals: ESR and spin trapping investigations. *Free Radic Biol Med* 1997; 23: 367–372.
15. Pappolla MA, Chyan YJ, Poeggeler B. An assessment of the antioxidant and anti-amyloidogenic properties of melatonin: implications for Alzheimer's disease. *J Neural Transm* 2000; 107: 203–231.
16. Bettahi I, Pozo D, Osuna C, Reiter RJ, Acuna-Castroviejo D, Guerrero JM. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. *J Pineal Res* 1996; 20: 205–210.
17. Liu RY, Zhou JN, van Heerikhuizen J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-ε4 genotype. *J Clin Endocrinol Metab* 1999; 84: 323–327.
18. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. *J Pineal Res* 2005; 38: 145–152.
19. Amuk T, Karadağ F, Oğuzhanoglu N, Oğuzhanoglu A. Cornell demansta depresyon ölçeği'nin Türk yaşlı toplumunda geçerlik ve güvenilirliği. *Türk Psikiyatri Dergisi* 2003; 14: 263–271 (in Turkish).
20. Reisberg B, Ferris SH, de Leon MJ. The global deterioration scale for assessment of primary degenerative dementia. *Am J Psychiatry* 1982; 139: 1136–1139.
21. Diker J, Etiler N, Yıldız M, Şeref B. Altmış beş yaş üzerindeki kişilerde bilişsel durumun günlük yaşam aktiviteleri, yaşam kalitesi ve demografik değişkenlerle ilişkisi. *Anadolu Psikiyatri Dergisi* 2001; 2: 79–86 (in Turkish).
22. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC, USA: APA; 1994.
23. Ceyhun B. Demansın psikolojik değerlendirilmesi. *Demans Dizisi* 1999; 3: 90–103.
24. Folstein MF, Folstein SF, McHugh PR. Mini Mental State: A practical method for grading the cognitive state of patients for the clinician. *J Psychiat Res* 1975; 12: 189–198.
25. Ertan T, Eker E, Güngen C, Engin F, Yaşar R, Kılıç G, Özel S. The Standardized Mini Mental State Examination for illiterate Turkish elderly population. In: *2nd International Symposium on Neurophysiological and Neuropsychological Assessment of Mental and Behavioral Disorders*; 1999.
26. Petersen RC, Smith GE, Waring SC, Ivnik RC, Tangalos EG, Kökmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 1999; 56: 303–308.
27. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. *Ann Neurol* 1998; 44: 410–413.
28. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. *FASEB J* 1998; 12: 1777–1783.
29. Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, Fitzgerald GA. Increased 8,12-iso-iPF_{2α}-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity. *Ann Neurol* 2000; 48: 809–812.
30. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, Cavalieri TA. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. *Brain Res Bull* 2001; 54: 565–568.
31. Pratico D, Clark CM, Linn F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. *Arch Neurol* 2002; 59: 972–976.
32. Irizary MC, Yao Y, Hyman BT, Growdon JH, Pratico D. Plasma F2 isoprostane levels in Alzheimer's and Parkinson's disease. *Neurodegener Dis* 2007; 4: 403–405.

33. Mufson E, Leurgans S. Inability of plasma and urine F₂-isoprostane levels to differentiate mild cognitive impairment from Alzheimer's disease. *Neurodegener Dis* 2010; 7: 139–142.
34. Kuo HC, Yen HC, Huang CC, Hsu WC, Wei HJ, Lin CL. Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease. *Int J Neurosci* 2014 (Epub ahead of print).
35. Wang J, Wang Z. Role of melatonin in Alzheimer-like neurodegeneration. *2006*; 27: 41–49.
36. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. *J Pineal Res* 2003; 35: 125–130.
37. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. *J Pineal Res* 2005; 8: 145–152.
38. Polimeni G, Esposito E, Bevelacqua V, Guarneri C, Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. *Front Biosci (Landmark Ed)* 2014; 19: 429–446 .
39. Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Marom AF, Zisapel N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. *Clin Interv Aging* 2014; 9: 947–961.
40. Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, van Kan HJ. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. *J Clin Endocrinol Metab* 2003; 88: 5898–5906.
41. Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. *Exp Gerontol* 2000; 35: 1239–1250.
42. Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. *Biol Psychiatry* 1999; 45: 1646–1652.